Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Stimulation of human EBV-and CMV-specific cytolytic effector function using allogeneic HLA molecules

D'Orsogna, L.J., van den Heuvel, H., van der Meer-Prins, E.M.W., Roelen, D.L., Doxiadis, I.I.N. and Claas, F.H.J. (2012) Stimulation of human EBV-and CMV-specific cytolytic effector function using allogeneic HLA molecules. The Journal of Immunology, 189 (10). pp. 4825-4831.

Free to read:
*No subscription required


Viral infection is a major cause of morbidity and mortality, and there are few therapeutic options available to augment a virusspecific T cell response. Although allo-HLA cross-reactivity from virus-specific memory T cells is common, it is unclear whether priming with specific allogeneic cells could conversely elicit a viral peptide/self-HLA restricted cytotoxic T cell response in humans. First, we used the previously described allo-HLA-B*44:0 - cross-reactivity of EBV peptide/HLA-B8 restricted T cells, to determine whether allogeneic HLA stimulation can elicit a cytolytic immune response against EBV. HLA-B8 + HLA-B44 - EBV-seropositive PBMCs were stimulated with either HLA-B*44:02 + or HLA-B*44:03 + mismatched irradiated PBMCs in a 7-10 d MLR. The allo-HLA stimulated responder cells were then evaluated for cytotoxicity using EBV peptide loaded autologous target cells and unloaded HLA-B8 + EBV LCL target cells. PBMCs from EBV-seropositive donors gained EBV-specific cytolytic effector function following specific allo-HLA stimulation. Finally, we also elicited cytolytic CMV-specific responses using specific allogeneic cell stimulation, to confirm that this technique can be used to elicit viral peptide/self-HLA restricted responses even from nonpublic TCR responses. Allogeneic cell stimulation used as a cell therapy may be a potential tool to augment an antiviral T cell response in patients with EBV or CMV infection.

Item Type: Journal Article
Murdoch Affiliation(s): Institute for Immunology and Infectious Diseases
Publisher: American Association of Immunologists
Copyright: © 2012 by The American Association of Immunologists, Inc
Item Control Page Item Control Page